Alchemab Therapeutics, a Cambridge, England, UK-based biotech company developing novel products for patients with diseases by harnessing naturally protective antibodies, completed a £60m ($82m) Series A financing round.
The round was led by RA Capital Management, with participation from Lightstone Ventures, Data Collective VC (DCVC), DHVC, SV Health Investors and the Dementia Discovery Fund.
The company, which was created by SV Health Investors who led the Seed round in 2019, intends to use the advance its target-agnostic drug discovery platform.
Founded in 2019 and led by Alex Leech, CEO, and Dr Jane Osbourn OBE, CSO, Alchemab has developed a platform which enables the identification of novel drug targets and therapeutics on the basis of patient B-cell antibody repertoires. The platform uses defined patient samples and a range of functional and advanced analytical techniques to evaluate convergent protective antibody responses in groups of individuals that are susceptible but resilient to specific diseases.
Alchemab is building a broad pipeline of protective therapeutics for hard-to-treat diseases, with an initial focus on oncology, neurodegenerative conditions and infectious diseases.